Skip to main content
Top
Published in: Osteoporosis International 10/2015

01-10-2015 | Original Article

A double-blind, randomized, Phase III, multicenter study in 358 pediatric subjects receiving isotretinoin therapy demonstrates no effect on pediatric bone mineral density

Authors: K. B. Hoover, C. G. Miller, N. C. Galante, C. B. Langman

Published in: Osteoporosis International | Issue 10/2015

Login to get access

Abstract

Summary

This study compared the effects of pediatric acne treatment with two isotretinoin formulations on bone mineral density. We demonstrated no difference in the effect of the two formulations. No effect on pediatric bone mineral density was identified for either formulation.

Introduction

Isotretinoin (13-cis-retinoic acid) is a treatment for recalcitrant nodular acne with a purported effect on bone mineral density (BMD). The side effects of isotretinoin on vertebral bone were evaluated to assess the safety of a new FDA-approved isotretinoin formulation: Lidose-isotretinoin (Cip-Iso).

Methods

This double-blind, randomized, phase III, active control, parallel-group, multicenter study compared the safety, efficacy, and non-inferiority of CIP-Iso to a marketed reference product, Accutane®, in severe recalcitrant nodular acne subjects. Three hundred fifty-eight pediatric male and female subjects aged between 12 and 17 years underwent 20 weeks of treatment with PA lumbar spine dual X-ray absorptiometry (DXA) measurements obtained for bone mineral density (BMD) and Z-scores, 5.5 months apart on visits 1 and 8. One hundred sixty-eight of 358 subjects had height adjusted Z-scores (HAZ) calculated.

Results

There was no difference in the least squares (LS) mean Z-score or HAZ of the two drugs at visit 1 or 8. The mean and LS mean Z-score and HAZ were greater than zero at visits 1 and 8 for both drugs. The change in the LS mean spine Z-score, but not HAZ, between visits, was statistically significant for both drugs. There was a mean increase in BMD (g/cm2) for both products between visits.

Conclusions

There is no difference in the effect of two formulations of isotretinoin on spine bone density after 6 months of treatment. BMD increased and the small change in spine Z-score over treatment disappeared after height adjustment. Mean positive Z-scores and HAZ in the study were likely due to the exclusion of low and inclusion of high Z-score subjects.
Literature
2.
go back to reference Leachman SA, Insogna KL, Katz L, Ellison A, Milstone LM (1999) Bone densities in patients receiving isotretinoin for cystic acne. Arch Dermatol 135:961–965CrossRefPubMed Leachman SA, Insogna KL, Katz L, Ellison A, Milstone LM (1999) Bone densities in patients receiving isotretinoin for cystic acne. Arch Dermatol 135:961–965CrossRefPubMed
3.
go back to reference Milstone LM, McGuire J, Ablow RC (1982) Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol 7:663–666CrossRefPubMed Milstone LM, McGuire J, Ablow RC (1982) Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol 7:663–666CrossRefPubMed
4.
go back to reference On SC, Zeichner J (2013) Isotretinoin updates. Dermatol Ther 26:377–389PubMed On SC, Zeichner J (2013) Isotretinoin updates. Dermatol Ther 26:377–389PubMed
5.
go back to reference Lawson JP, McGuire J (1987) The spectrum of skeletal changes associated with long-term administration of 13-cis-retinoic acid. Skelet Radiol 16:91–97CrossRef Lawson JP, McGuire J (1987) The spectrum of skeletal changes associated with long-term administration of 13-cis-retinoic acid. Skelet Radiol 16:91–97CrossRef
6.
go back to reference Milstone LM, Ellison AF, Insogna KL (1992) Serum parathyroid hormone level is elevated in some patients with disorders of keratinization. Arch Dermatol 128:926–930CrossRefPubMed Milstone LM, Ellison AF, Insogna KL (1992) Serum parathyroid hormone level is elevated in some patients with disorders of keratinization. Arch Dermatol 128:926–930CrossRefPubMed
7.
go back to reference DiGiovanna JJ, Sollitto RB, Abangan DL, Steinberg SM, Reynolds JC (1995) Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol 131:1263–1267CrossRefPubMed DiGiovanna JJ, Sollitto RB, Abangan DL, Steinberg SM, Reynolds JC (1995) Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol 131:1263–1267CrossRefPubMed
8.
go back to reference Margolis DJ, Attie M, Leyden JJ (1996) Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin for acne vulgaris. Arch Dermatol 132:769–774CrossRefPubMed Margolis DJ, Attie M, Leyden JJ (1996) Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin for acne vulgaris. Arch Dermatol 132:769–774CrossRefPubMed
9.
go back to reference Tekin NS, Ozdolap S, Sarikaya S, Keskin SI (2008) Bone mineral density and bone turnover markers in patients receiving a single course of isotretinoin for nodulocystic acne. Int J Dermatol 47:622–625CrossRefPubMed Tekin NS, Ozdolap S, Sarikaya S, Keskin SI (2008) Bone mineral density and bone turnover markers in patients receiving a single course of isotretinoin for nodulocystic acne. Int J Dermatol 47:622–625CrossRefPubMed
10.
go back to reference Erdogan BS, Yuksel D, Aktan S, Ergin S, Kirac FS (2006) The effects of isotretinoin treatment on bone mineral density in patients with nodulocystic acne. J Eur Acad Dermatol Venereol 20:1006–1007CrossRefPubMed Erdogan BS, Yuksel D, Aktan S, Ergin S, Kirac FS (2006) The effects of isotretinoin treatment on bone mineral density in patients with nodulocystic acne. J Eur Acad Dermatol Venereol 20:1006–1007CrossRefPubMed
11.
go back to reference DiGiovanna JJ, Langman CB, Tschen EH, Jones T, Menter A, Lowe NJ, Eichenfield L, Hebert AA, Pariser D, Savin RP, Smith SR, Jarratt M, Rodriguez D, Chalker DK, Kempers S, Ling M, Rafal ES, Sullivan S, Kang S, Shah LP, Wu E, Newhouse J, Pak J, Eberhardt DR, Bryce GF, McLane JA, Ondovik M, Chin C, Khoo KC, Rich P (2004) Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. J Am Acad Dermatol 51:709–717CrossRefPubMed DiGiovanna JJ, Langman CB, Tschen EH, Jones T, Menter A, Lowe NJ, Eichenfield L, Hebert AA, Pariser D, Savin RP, Smith SR, Jarratt M, Rodriguez D, Chalker DK, Kempers S, Ling M, Rafal ES, Sullivan S, Kang S, Shah LP, Wu E, Newhouse J, Pak J, Eberhardt DR, Bryce GF, McLane JA, Ondovik M, Chin C, Khoo KC, Rich P (2004) Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. J Am Acad Dermatol 51:709–717CrossRefPubMed
12.
go back to reference Baim S, Leonard MB, Bianchi ML, Hans DB, Kalkwarf HJ, Langman CB, Rauch F (2008) Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom 11:6–21CrossRefPubMed Baim S, Leonard MB, Bianchi ML, Hans DB, Kalkwarf HJ, Langman CB, Rauch F (2008) Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom 11:6–21CrossRefPubMed
13.
go back to reference Lorente-Ramos R, Azpeitia-Arman J, Munoz-Hernandez A, Garcia-Gomez JM, Diez-Martinez P, Grande-Barez M (2011) Dual-energy x-ray absorptiometry in the diagnosis of osteoporosis: a practical guide. AJR Am J Roentgenol 196:897–904CrossRefPubMed Lorente-Ramos R, Azpeitia-Arman J, Munoz-Hernandez A, Garcia-Gomez JM, Diez-Martinez P, Grande-Barez M (2011) Dual-energy x-ray absorptiometry in the diagnosis of osteoporosis: a practical guide. AJR Am J Roentgenol 196:897–904CrossRefPubMed
14.
go back to reference Vestergaard P, Rejnmark L, Mosekilde L (2010) High-dose treatment with vitamin A analogues and risk of fractures. Arch Dermatol 146:478–482CrossRefPubMed Vestergaard P, Rejnmark L, Mosekilde L (2010) High-dose treatment with vitamin A analogues and risk of fractures. Arch Dermatol 146:478–482CrossRefPubMed
15.
go back to reference Webster GF, Leyden JJ, Gross JA (2014) Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-lidose in patients with severe recalcitrant nodular acne. J Drugs Dermatol 13:665–670PubMed Webster GF, Leyden JJ, Gross JA (2014) Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-lidose in patients with severe recalcitrant nodular acne. J Drugs Dermatol 13:665–670PubMed
16.
go back to reference Webster GF, Leyden JJ, Gross JA (2013) Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study. J Am Acad Dermatol 69:762–767CrossRefPubMed Webster GF, Leyden JJ, Gross JA (2013) Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study. J Am Acad Dermatol 69:762–767CrossRefPubMed
17.
go back to reference Zemel BS, Leonard MB, Kelly A, Lappe JM, Gilsanz V, Oberfield S, Mahboubi S, Shepherd JA, Hangartner TN, Frederick MM, Winer KK, Kalkwarf HJ (2010) Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab 95:1265–1273PubMedCentralCrossRefPubMed Zemel BS, Leonard MB, Kelly A, Lappe JM, Gilsanz V, Oberfield S, Mahboubi S, Shepherd JA, Hangartner TN, Frederick MM, Winer KK, Kalkwarf HJ (2010) Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab 95:1265–1273PubMedCentralCrossRefPubMed
18.
go back to reference Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL (2000) CDC growth charts: United States. Adv Data 314:1–27PubMed Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL (2000) CDC growth charts: United States. Adv Data 314:1–27PubMed
19.
go back to reference Gordon CM, Leonard MB, Zemel BS, International Society for Clinical Densitometry (2014) 2013 Pediatric Position Development Conference: executive summary and reflections. J Clin Densitom 17:219–224CrossRefPubMed Gordon CM, Leonard MB, Zemel BS, International Society for Clinical Densitometry (2014) 2013 Pediatric Position Development Conference: executive summary and reflections. J Clin Densitom 17:219–224CrossRefPubMed
20.
go back to reference Desmangles JC, Lappe JM, Lipaczewski G, Haynatzki G (2006) Accuracy of pubertal Tanner staging self-reporting. J Pediatr Endocrinol Metab 19:213–221CrossRefPubMed Desmangles JC, Lappe JM, Lipaczewski G, Haynatzki G (2006) Accuracy of pubertal Tanner staging self-reporting. J Pediatr Endocrinol Metab 19:213–221CrossRefPubMed
21.
go back to reference Shepherd JA, Wang L, Fan B, Gilsanz V, Kalkwarf HJ, Lappe J, Lu Y, Hangartner T, Zemel BS, Fredrick M, Oberfield S, Winer KK (2011) Optimal monitoring time interval between DXA measures in children. J Bone Miner Res 26:2745–2752PubMedCentralCrossRefPubMed Shepherd JA, Wang L, Fan B, Gilsanz V, Kalkwarf HJ, Lappe J, Lu Y, Hangartner T, Zemel BS, Fredrick M, Oberfield S, Winer KK (2011) Optimal monitoring time interval between DXA measures in children. J Bone Miner Res 26:2745–2752PubMedCentralCrossRefPubMed
22.
go back to reference Roche Pharmaceuticals (2010) Medication guide accutane. 2014 Roche Pharmaceuticals (2010) Medication guide accutane. 2014
Metadata
Title
A double-blind, randomized, Phase III, multicenter study in 358 pediatric subjects receiving isotretinoin therapy demonstrates no effect on pediatric bone mineral density
Authors
K. B. Hoover
C. G. Miller
N. C. Galante
C. B. Langman
Publication date
01-10-2015
Publisher
Springer London
Published in
Osteoporosis International / Issue 10/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3158-2

Other articles of this Issue 10/2015

Osteoporosis International 10/2015 Go to the issue